Press Release: Mergers: European Commission clears planned acquisition of Ratiopharm by Teva, subject to conditions

The European Commission has approved under the EU Merger Regulation the proposed acquisition of the German generic pharmaceutical company Ratiopharm by Teva, Israel.

The decision is conditional upon the divestment of fifteen products in the Netherlands and one in Hungary. The Commission had concerns that the parties' high combined market shares for these products, together with their overall post-merger strength in the Netherlands, could have harmed competition on these markets.

In the light of the commitments, the Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.